Text and Data Mining valid from 2019-11-07
Received: 3 August 2019
Accepted: 22 October 2019
First Online: 7 November 2019
Ethics approval and consent to participate
: This trial has been approved by the institutional review boards (ID: 2016-XY-023) and the independent ethics committees of Sun Yat-sen University Cancer Center (Ethic approval ID: 5010-2016-03). And other participating centers have also provided approval from their institutional review boards/independent ethics committees before enrollment. All patients were required to sign an informed consent form before enrollment.
: The authors are fully responsible for all content and editorial decisions were involved at all stages of manuscript development, and have approved the final version.
: Li Zhang has received research support from Hengrui Medicine Co. Ltd, Eli Lilly, Novartis Switzerland. Co. Ltd., Roche Shanghai. Co. Ltd., and Bristol-Myers Squibb Shanghai. Co. Ltd. All other authors declare that they have no competing interests.